STOCK TITAN

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags

Cardiff Oncology (Nasdaq: CRDF) has announced the pricing of an oversubscribed underwritten registered direct offering of 15,384,619 common stock shares at $2.60 per share, aiming to raise approximately $40 million in gross proceeds. The offering attracted new mutual fund and healthcare dedicated investors, alongside existing investors' support.

The company plans to use the net proceeds to fund clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) and for working capital. TD Cowen is leading the offering as book-runner, with William Blair, H.C. Wainwright & Co., and Craig-Hallum also participating in various roles. The offering is expected to close around December 11, 2024.

Cardiff Oncology (Nasdaq: CRDF) ha annunciato il prezzo di un offerta diretta registrata sottoscritta di 15.384.619 azioni ordinarie a $2,60 per azione, con l'obiettivo di raccogliere circa $40 milioni di proventi lordi. L'offerta ha attratto nuovi investitori istituzionali e investitori dedicati alla sanità, oltre al supporto di investitori esistenti.

La società prevede di utilizzare i proventi netti per finanziare i costi clinici per onvansertib nel trattamento del cancro colorettale metastatico (mCRC) con mutazioni RAS in prima linea e per il capitale circolante. TD Cowen è il book-runner dell'offerta, con William Blair, H.C. Wainwright & Co. e Craig-Hallum che partecipano anche in vari ruoli. Si prevede che l'offerta si chiuda intorno all'11 dicembre 2024.

Cardiff Oncology (Nasdaq: CRDF) ha anunciado la fijación del precio de una oferta directa registrada suscrita de 15.384.619 acciones ordinarias a $2.60 por acción, con el objetivo de recaudar aproximadamente $40 millones en ingresos brutos. La oferta atrajo nuevos inversores de fondos mutuos y dedicados al sector salud, además del apoyo de inversores existentes.

La compañía planea utilizar los ingresos netos para financiar los costos clínicos de onvansertib en el tratamiento del cáncer colorrectal metastásico (mCRC) con mutaciones RAS en primera línea y para capital de trabajo. TD Cowen lidera la oferta como book-runner, con William Blair, H.C. Wainwright & Co. y Craig-Hallum también participando en varios roles. Se espera que la oferta se cierre alrededor del 11 de diciembre de 2024.

카디프 온콜로지 (Nasdaq: CRDF)는 15,384,619주를 주당 $2.60에 발행하는 공모 직상장 보증의 가격을 발표했으며, 약 $40 백만을 조달할 계획입니다. 이번 공모는 새로운 뮤추얼 펀드 및 헬스케어 전용 투자자를 유치하였고 기존 투자자들의 지원도 받았습니다.

회사는 순수익을 이용하여 첫 번째 라인 RAS 변이 전이성 대장암(mCRC)에서 온반서틴의 임상 비용을 지원하고 운전 자본으로 사용할 예정입니다. TD Cowen이 북런너로서 이번 공모를 이끌고 있으며, 윌리엄 블레어, H.C. 웨인라이트 & 코, 그리고 크레이그-할럼이 여러 역할로 참여하고 있습니다. 이번 공모는 2024년 12월 11일경 마감될 예정입니다.

Cardiff Oncology (Nasdaq: CRDF) a annoncé le prix d'une offre directe enregistrée souscrite de 15.384.619 actions ordinaires à 2,60 $ par action, visant à lever environ 40 millions de dollars de produits bruts. L'offre a attiré de nouveaux investisseurs en fonds communs et des investisseurs spécialisés dans la santé, en plus du soutien des investisseurs existants.

La société prévoit d'utiliser les produits nets pour financer les coûts cliniques de onvansertib dans le traitement du cancer colorectal métastatique (mCRC) avec mutation RAS en première ligne et pour le fonds de roulement. TD Cowen dirige l'offre en tant que book-runner, avec participation de William Blair, H.C. Wainwright & Co. et Craig-Hallum dans divers rôles. L'offre devrait se clôturer aux alentours du 11 décembre 2024.

Cardiff Oncology (Nasdaq: CRDF) hat die Preis Festlegung eines unterzeichneten registrierten Direktofferten von 15.384.619 Stammaktien zu $2,60 pro Aktie bekannt gegeben, mit dem Ziel, etwa $40 Millionen an Bruttoerträgen zu erzielen. Das Angebot zog neue Investoren von Mischfonds und aus dem Gesundheitssektor an, zusätzlich zur Unterstützung bestehender Investoren.

Das Unternehmen plant, die Nettomittel zur Finanzierung der klinischen Kosten für onvansertib bei RAS-mutiertem metastatischem kolorektalem Krebs (mCRC) in der ersten Linie sowie für das Betriebskapital zu verwenden. TD Cowen führt das Angebot als Bookrunner, wobei William Blair, H.C. Wainwright & Co. und Craig-Hallum ebenfalls in verschiedenen Rollen teilnehmen. Das Angebot wird voraussichtlich am 11. Dezember 2024 abgeschlossen.

Positive
  • Successfully secured $40 million in gross proceeds through oversubscribed offering
  • Attracted new mutual fund and healthcare dedicated investors
  • Maintained support from existing investors
Negative
  • Significant shareholder dilution through issuance of 15,384,619 new shares
  • Share offering priced at $2.60, which may represent a discount to market price

Insights

This $40 million registered direct offering marks a significant capital raise for Cardiff Oncology, priced at $2.60 per share. The oversubscribed nature and participation from new mutual fund and healthcare investors signals strong institutional confidence in the company's PLK1 inhibition platform. The financing strengthens their balance sheet and provides important runway for advancing their lead candidate onvansertib in RAS-mutated metastatic colorectal cancer trials. However, the offering price represents a discount to recent trading levels, which could create near-term dilution pressure. The involvement of prominent underwriters like TD Cowen and William Blair adds credibility to the transaction. This funding should extend their operational timeline well into 2025.

The capital raise provides critical funding for Cardiff's clinical development of onvansertib in first-line RAS-mutated mCRC, an area with significant unmet medical need. RAS mutations are present in approximately 45% of colorectal cancer cases and are associated with poor prognosis and treatment resistance. The PLK1 inhibition approach represents a novel therapeutic strategy in this space. The strong investor interest, particularly from healthcare-dedicated funds, suggests confidence in the clinical potential of onvansertib and Cardiff's development strategy. This funding should enable completion of key clinical milestones and potential advancement toward late-stage trials.

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the pricing of an underwritten offering of 15,384,619 shares of its common stock at an offering price of $2.60 per share, before deducting underwriting discounts and commissions. All of the shares of common stock are being offered by the Company. The financing included participation from new mutual fund and healthcare dedicated investors, along with support from existing investors.

The gross proceeds to the Company, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $40 million. The offering is expected to close on or about December 11, 2024, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from this offering to fund clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) and for working capital and other general corporate purposes.

TD Cowen is acting as lead book-runner for the offering. William Blair is also acting as book-runner, H.C. Wainwright & Co. is acting as lead manager, and Craig-Hallum is acting as co-manager for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 previously filed with the U.S. Securities and Exchange Commission (“SEC”) and declared effective by the SEC on April 25, 2022. A prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus, may be obtained, when available, by contacting TD Securities (USA) LLC, 1 Vanderbilt Ave., New York, NY 10017, by telephone at (855) 495-9846, or by email at TD.ECM_Prospectus@tdsecurities.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern the Company’s expectations, strategy, plans or intentions. These forward-looking statements are based on the Company’s current expectations and actual results could differ materially. Forward-looking statements include statements regarding the closing of the offering of common stock; and the Company’s intended use of proceeds. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the satisfaction of customary closing conditions related to the offering, our need for additional financing; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; the Company’s clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of the Company’s product candidate; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain U.S. Food and Drug Administration (“FDA”) clearances or approvals and noncompliance with FDA regulations. There are no guarantees that the Company’s product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the SEC. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and the Company does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com

Investor Contact:
Kiki Patel, PharmD 
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com

Media Contact:
Grace Spencer
Taft Communications
609-583-1151
grace@taftcommunications.com


FAQ

How much did Cardiff Oncology raise in their December 2024 offering?

Cardiff Oncology raised approximately $40 million in gross proceeds through an underwritten registered direct offering of 15,384,619 shares priced at $2.60 per share.

What will Cardiff Oncology (CRDF) use the proceeds for?

The proceeds will be used to fund clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) and for working capital and general corporate purposes.

When is Cardiff Oncology's (CRDF) December 2024 offering expected to close?

The offering is expected to close on or about December 11, 2024, subject to customary closing conditions.

How many shares did Cardiff Oncology (CRDF) offer in their December 2024 financing?

Cardiff Oncology offered 15,384,619 shares of common stock at a price of $2.60 per share.
Cardiff Oncology Inc

NASDAQ:CRDF

CRDF Rankings

CRDF Latest News

CRDF Stock Data

202.57M
61.25M
5.62%
39.03%
17.11%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO